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All readers of the Community Eye Health 
Journal who are responsible for 
managing trachoma programmes at 
national, regional, or district level need 
to be familiar with the requirements for 
Zithromax® donation. The generous 
global donation of the antibiotic 
Zithromax® by Pfi  zer Inc. through the 
International Trachoma Initiative (ITI) can 
play an important role in the successful 
elimination of blinding trachoma. 
Therefore, the procedures required to 
apply for and manage the product need 
to be understood and followed. 
Countries obtain donated Zithromax® 
through an application to ITI. The appli-
cation is a cooperative process through 
which ITI, governments of trachoma-
endemic countries, and other partners 
work together towards the national goal of 
eliminating blindness caused by 
trachoma.
Since 1998, ITI has managed Pfi  zer’s 
donation of Zithromax® . This drug is an 
effective broad-spectrum antibiotic that, 
when administered once annually for a 
consecutive number of years, works to 
reduce the reservoir of Chlamydia tracho-
matis infection in endemic communities. 
By distributing antibiotics in conjunction 
with surgical interventions, health 
education, and increased access to water 
and sanitation (known as the SAFE 
strategy), national trachoma programmes 
can stop disease transmission and 
progression to blindness.
Since the International Trachoma 
Initiative’s inception, Zithromax® has 
been donated to 23 countries and over 
two hundred million doses have been 
administered. Careful planning is required 
to ensure that national programmes 
receive the right quantity of drugs in a 
timely manner and that appropriate 
supply chain systems are in place to 
manage the product when it arrives in the 
country where it will be used.
Application
The Zithromax® application process starts 
nearly eighteen months before the drug 
arrives at its destination. It requires a 
dialogue between the relevant ministries 
of health, ITI, Pfi  zer, and international 
implementing partners (non-govern-
mental organisations). The complex 
supply chain begins with Pfi  zer’s 
suppliers, who provide raw materials, 
bottles, and packaging. Pfi  zer then 
manufactures the drug and arranges 
transport to the endemic countries. On 
arrival, the government, represented by 
the ministry of health, is expected to clear 
the drugs, store them safely, manage 
their distribution through mass drug 
administration (MDA), and implement the 
other elements of the SAFE strategy. 
ITI works directly with national 
trachoma programme managers who are 
designated by the ministry of health. ITI 
sends a new application form each year in 
November and the ministry must submit 
the completed application by February 
the following year. The application 
includes district-level data on past treat-
ments, the latest trachoma prevalence 
data, a long-term forecast, and a current 
drug inventory. Despite the diffi  culty of 
forecasting in the long term, a 3–5 year 
needs assessment is critical to planning. 
The application process allows ITI to see 
whether there are programme gaps, 
allows Pfi  zer to plan raw material require-
ments, and allows the ministry of health 
to review their country plans and to 
ensure that partners are available to 
assist with all aspects of the SAFE 
strategy. 
Between February and April, ITI 
analyses the data on drug requirements 
from all existing countries and new country 
applicants. Prior to the World Health 
Organization (WHO) annual trachoma 
alliance meeting (GET2020) in April,
each country representative meets with 
members of ITI, Pfi  zer, WHO, and other 
implementing partners and key stake-
holders in order to review the plan and 
produce a forecast of Zithromax require-
ments. This meeting also provides an 
opportunity to assess partner support for 
SAFE strategy implementation and to 
review baseline and impact prevalence 
surveys. 
From these meetings, Pfi  zer can 
determine the overall drug requirements. 
The company can then plan manufac-
turing capacity for the following year, 
taking into account other business 
requirements. Any missing or additional 
data required for the applications is 
followed up by ITI in May. 
In June, a fi  nal Zithromax® application 
is reviewed by the Trachoma Expert 
Committee (TEC), an independent body 
of international experts in public health, 
ophthalmology, blindness prevention, and 
the SAFE Strategy. TEC members provide 
guidance to ITI on strategic, technical and 
operational issues during two semi-
annual meetings. Based on the TEC 
recommendations, each ministry of 
health applying for Zithromax® is sent 
either a memorandum of understanding 
(MOU) for the following year detailing the 
quantity of Zithromax® and the districts 
approved for distribution, or a letter 
explaining why the country application 
was unsuccessful with suggestions to 
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Boxes of Zithromax, ® ready for mass drug administration in a community. uGanDa.
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help the country to meet requirements in 
the future. 
Once the MOU has been signed by the 
ministry and returned to ITI, delivery of 
Zithromax® is scheduled for approximately 
one to two months prior to the time when 
MDA is to take place. For countries that are 
already involved and that have received 
Zithromax® in past years, there needs to be 
an updated inventory of any drugs already in 
the country, including those with a short 
shelf life and those about to expire. On the 
basis of this information, adjustments to 
the donation forecast are made. 
Supply	chain	
Currently, Zithromax® is manufactured in 
two formulations, pediatric powder for oral 
suspension for children ages six months to 
fi  ve years, and tablets for people over fi  ve 
years of age. The product is manufactured 
at various sites in Europe or the USA. Once 
manufactured, the product is stored in one 
of Pfi  zer’s European warehouse locations 
where the goods await allocation to 
recipient countries. Due to the large size of 
each shipment (hundreds of pallets for 
each country), several airplane loads may 
be required. Upon arrival in the country, the 
ministry of health must ensure customs 
clearance and transport to central medical 
stores and to regional warehouses in prepa-
ration for MDA. All charges are the responsibility 
of the ministry of health. A detailed 
description of best practices for in-country 
supply chain can be found in “Zithromax®
in the Elimination of Blinding Trachoma:
A Program Manager’s Guide” at
www.trachoma.org/guides-and-manuals
Countries	seeking	
Zithromax®
The Zithromax® donation is available only to 
governments of poor endemic countries for 
the elimination of blinding trachoma. 
Countries that have been approved for the 
donation may use it for MDA, adminis-
tration after trichiasis surgery, or as part of 
surveillance or prevalence surveys, in 
addition to special pre-approved uses by ITI 
and the TEC. 
National ownership and proven 
commitment to the elimination goal is key 
for a successful application and continued 
donation of Zithromax® . The requirements 
for Zithromax® donation (including evidence 
of need, training of health care staff, SAFE 
strategy implementation, effective distri-
bution strategies, and monitoring and 
evaluation) may be demanding for under-
resourced and overstretched national 
health programmes. However, they are 
necessary to manage and monitor the 
Zithromax® donation to aid in the elimi-
nation of this painful and blinding disease. 
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EXCHAnGE
USEFUL	RESOURCES
Dear Editor,
Those of us who are extracapsular 
cataract surgeons have all experienced 
delays in cauterizing the eye due to 
diffi  culty in lighting a spirit lamp 
containing methylated spirit with too 
much water mixed in it. What should be 
a simple and short stage of the 
operation becomes tense and 
prolonged, cautery may be inadequate, 
and there is ineffi  cient use of anaes-
thetic time.
We have found that using a cigarette 
lighter for heating is a viable alter-
native.
In Tanzania, the cigarette lighter 
illustrated is easily available and can be 
purchased cheaply from local stores, 
costing only TZS 500 (around US $0.30). 
The fl  ame effectively heats the ball of 
the Wordsworth cautery, and soot 
accumulation can be avoided if the 
cautery is held in the blue rather than 
the yellow part of the fl  ame.
So far, we have tested two models of 
cheap lighter. Not all are 
suitable, as the top of the 
lighter becomes hot and 
parts may melt during 
prolonged use. For this 
reason also we 
recommend that surgical 
gloves are not worn by the 
person holding the lighter. 
When using a lighter of the 
type illustrated, we have 
found this method to be 
safe, easy to operate, and 
effective both in our own theatre and 
on outreach.
Using a lighter will also reduce the 
risks of fi  re in the theatre caused by 
gowns or drapes coming in contact with 
the fl  ame of an unattended spirit lamp, 
when operator or assistant are 
absorbed by a challenging 
operation. I have seen this 
once: surgical gowns are 
surprisingly fl  ammable! 
In general anaesthetic 
situations, the usual 
precautions regarding 
infl  ammable gases and 
naked fl  ames should be 
observed.
brian	Savage
Ophthalmologist, Haydom and 
KCMC Hospitals, Tanzania.
Using a lighter to heat
a cautery
Examples of the lighter 
we have found effective
Wordsworth cautery being heated in 
blue part of the ﬂ  ame. (the ﬂ  ame 
here is turned much higher than 
normal for illustration purposes)
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Diabetic	retinopathy
book
Diabetic retinopathy 
for the comprehensive 
ophthalmologist.
Walker J.
This book will be available 
in electronic format on the 
new Community Eye 
Health Update CD, due 
out with the December 
2011 edition of this 
journal. Look out for your 
free copy! The book is also available for 
purchase (US $39.99, soft cover, free delivery) 
or free download (nine PDF fi  les of 14–59MB 
each) from http://drcobook.com. Please note 
that the book is now three years old and that 
new information has become available, in 
particular about intravitreal injections. However, 
the book also covers timeless topics such as 
informed consent and diabetes control. 
Online	resources	
Diabetes grading scheme: International 
Clinical Diabetic Retinopathy And Diabetic 
Macular Edema Disease Severity Scales. 
International Council of Ophthalmology, 
October 2002.
http://archive.icoph.org/standards/gdrp.html 
Patient information about diabetic 
retinopathy (pdf, 200KB)
www.retinalscreening.nhs.uk/userFiles/
File/diabeticretinopathyFacts.pdf 
Patient information about a Dr screening 
programme: examples in several languages 
(PDF, 356KB maximum) www.dhsspsni.gov.
uk/public_health_diabetic_retinopathy
Detailed patient information about screening 
for Dr (pdf, 200KB) www.retinalscreening.nhs. 
uk/userFiles/File/EyeScreeningForDiabetes.pdf
Patient information about laser treatment 
(pdf, 200KB)
www.retinalscreening.nhs.uk/ userFiles/
File/PreparingForlasertreatmentDr.pdf
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